

## 510(k) Summary of Safety and Effectiveness

---

<b>Statement</b>	Information supporting claims of substantial equivalence, as defined under the Federal Food, Drug and Cosmetic Act, respecting safety and effectiveness is summarized below. For the convenience of the Reviewer, this summary is formatted in accordance with the Agency's final rule "...510(k) Summaries and 510(k) Statements..." (21 CFR §807) and can be used to provide a substantial equivalence summary to anyone requesting it from the Agency.
<b>Device description</b>	<p>The Niobe Magnetic Navigation System [MNS] is an interventional workstation for the navigation of appropriately equipped, magnetically adapted, devices (e.g., catheters or guidewires) through tissue to designated target sites. The system uses computer-controlled permanent magnets for orienting the tip of a magnetic device.</p> <p>The system employs magnetic fields to <i>orient</i> or <i>steer</i> the tip of a magnetic device.</p>
<b>Intended use</b>	The Niobe MNS is intended to navigate a magnetic device through tissue to designated target sites in the right and left heart and coronary vasculature by orienting the device tip in a desired direction.
<b>Substantial equivalence</b>	The Niobe MNS is substantially equivalent to the Telstar Magnetic Navigation System [MNS], K013484.
<b>Technological characteristics</b>	The Niobe Magnetic Navigation System employs application of magnetic fields to orient the distal tip of a magnetically-adapted device (e.g., catheter or guidewire).

---

*Continued on next page*

## 510(k) Summary of Safety and Effectiveness, Continued

### Device comparisons – steering control

The following is a comparison of the key features of the Niobe MNS vs. the predicate device, the Telstar MNS, K013484.

<b>Device Characteristics</b>	<b>New Device- Niobe MNS</b>	<b>Predicate Device- Telstar MNS</b>
Intended use	To navigate a magnetic device through tissue to designated target sites in the right and left heart and coronary vasculature by orienting the device tip in a desired direction.	To navigate a magnetic device through tissue to designated target sites in the right and left heart and coronary vasculature by orienting the device tip in a desired direction.
Direct contact with patient tissue	No	No
Remote tableside physician control of steerable device distal orientation	Yes	Yes
Computer control of steerable device distal orientation	Yes	Yes
Conducted under fluoroscopic visualization	Yes	Yes

*Continued on next page*

## 510(k) Summary of Safety and Effectiveness, Continued

---

<b>Physical testing</b>	Performance testing has demonstrated substantial equivalence of the new device to the predicate device.
-------------------------	---

---

<b>Preclinical animal and clinical performance data</b>	The Niobe MNS is a modification of the predicate Telstar MNS. Clinical data are not necessary to support the modifications. Clinical application data for magnetic navigation were provided in K013484. Performance of the Niobe MNS was demonstrated in three canine studies.
---	--

---

<b>Contact</b>	Peter A. Takes, Ph.D., RAC Director, Clinical & Regulatory Affairs Stereotaxis, Inc. 4041 Forest Park Avenue St. Louis, Missouri 63108 Ph. 314-615-6964 Fax 314-615-6912
----------------	--

---

<b>Date</b>	January 14, 2003
-------------	------------------

---



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JAN 15 2003

Stereotaxis, Inc.  
c/o Peter A. Takes, Ph.D., RAC  
Director  
Clinical and Regulatory Affairs  
4041 Forest Park Avenue  
St. Louis, Missouri 63108

Re: K021555  
Trade Name: Niobe™ Magnetic Navigation System  
Regulation Number: 21 CFR 870.1290  
Regulation Name: Steerable Catheter Control System  
Regulatory Class: Class II (two)  
Product Code: DXX  
Dated: December 6, 2002  
Received: December 9, 2002

Dear Dr. Takes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Bram D. Zuckerman', with a long horizontal flourish extending to the right.

Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Appendix 2: Indications for Use Statement



**Statement**

Indications for Use Statement:

510(k) Number: K 021555

Device Name: Niobe Magnetic Navigation System [MNS]

Indications for Use: The Niobe MNS is intended to navigate a magnetic device through tissue to designated target sites in the right and left heart and coronary vasculature by orienting the device tip in a desired direction.

  
(Division S...  
Division of ...  
 510(k) number K021555

Prescription Use ✓